SCHEMBL15055040

SCHEMBL15055040

O=C(OCCCN1CCOCC1)c1ccc(NS(=O)(=O)c2cc(-c3ccc4c(c3)CCO4)c(Cl)s2)cc1OC(=O)C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PFKFB3 Q16875 2/20 0.41
EPHX2 P34913 7/20 0.34
PTGS2 P35354 2/20 0.33
KDR P35968 2/20 0.33
FABP4 P15090 2/20 0.33
PTGS1 P23219 1/20 0.33
MCL1 Q07820 1/20 0.33
UTS2R Q9UKP6 1/20 0.32
KIT P10721 1/20 0.32
FABP3 P05413 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15059166 0.91 PFKFB3 (0.52) PFKFB3EPHX2PTGS2KDRPTGS1
Trifluoroacetic Acid SCHEMBL16393839 0.89 PFKFB3 (0.49) PFKFB3EPHX2PTGS2FABP4PTGS1
SCHEMBL15080000 0.88 PFKFB3 (0.52) PFKFB3EPHX2PTGS2FABP4PTGS1
SCHEMBL15055272 0.87 EPHX2 (0.40) PFKFB3EPHX2KDR
SCHEMBL15055366 0.85 EPHX2 (0.40) EPHX2UTS2R
SCHEMBL15056373 0.85 EPHX2 (0.42) PFKFB3EPHX2PTGS2PTGS1MCL1
SCHEMBL15055922 0.84 KDM4E (0.38) PFKFB3EPHX2PTGS2KIT
SCHEMBL15055682 0.84 EPHX2 (0.40) PFKFB3EPHX2PTGS2PTGS1
Trifluoroacetic Acid SCHEMBL15059167 0.81 PFKFB3 (0.62) PFKFB3EPHX2PTGS2PTGS1MCL1
SCHEMBL15055348 0.79 HRH3 (0.38) UTS2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2016-08-04 US claimed
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2015-01-22 US claimed
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2018-06-19 US disclosed
EP-2794009-B1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2017-08-30 EP disclosed
US-9718809-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2017-08-01 US disclosed
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2016-08-04 US disclosed
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2015-01-22 US disclosed
EP-2794009-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER Kancera AB (SE) 2014-10-29 EP disclosed
WO-2013093095-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2013-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER NFKBIA, IL6, LITAF PFKFB3 909/4885EPHX2 2619/4885PTGS2 128/4885
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER NFKBIA, IL6, LITAF PFKFB3 988/4885EPHX2 2645/4885PTGS2 135/4885
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer NFKBIA, IL6, LITAF PFKFB3 988/4885EPHX2 2645/4885PTGS2 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.